<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306124</url>
  </required_header>
  <id_info>
    <org_study_id>LL_001 Project on Dementia/MCI</org_study_id>
    <nct_id>NCT00306124</nct_id>
  </id_info>
  <brief_title>Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment</brief_title>
  <official_title>Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <brief_summary>
    <textblock>
      This study aims to determine whether levodopa is effective in boosting learning and memory in
      healthy subjects and patients with dementia or Mild Cognitive Impairment.

      We also examine in healthy subjects using functional magnetic resonance imaging which brain
      regions mediate improved learning after levodopa administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior work of our group shows that the dopamine precursor levodopa markedly improves word
      learning success in healthy subjects. In this randomized, placebo-controlled, double-blind
      trial, we probe whether administration of levodopa improves learning performance as compared
      to placebo administration on neuropsychological tests and in an associative learning
      paradigm. We postulate that levodopa improves learning success and memory performance in
      healthy subjects, while the effect in patients with dementia or Mild Cognitive Impairment
      might depend on other factors, including severity of memory impairment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive performance assessed by neuropsychological tests and learning paradigms under placebo and levodopa in healthy subjects and patients with dementia or Mild Cognitive Impairment.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain activity pattern during learning under levodopa as compared to placebo in healthy subjects.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term stability of learning performance after 1 month in healthy subjects.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for patients with dementia:

          -  Patients: clinical diagnosis of AD or mild cognitive impairment

          -  primary language German

        Exclusion Criteria for healthy subjects and patients with dementia/MCI:

          -  Known allergy to levodopa or tetrazine

          -  History of medication/drug abuse

          -  Acute nicotine withdrawal or &gt; 15 cigarettes per day

          -  &gt; 6 cups/glasses of coffee, caffeine drinks or energy drinks per day

          -  &gt; 50 grams of alcohol per day

          -  Severe hypertonia (systole &gt;160 mm Hg)

          -  Severe arteriosclerosis

          -  Diabetes, asthma, or glaucoma

          -  Severe hearing disability

          -  no focal brain lesions

          -  Premorbid depression or psychosis

          -  Medication with dopamine agonists or antagonists

          -  Parkinsonian symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Knecht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology, University of Muenster, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caterina Breitenstein, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology, University of Muenster, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia Reinholz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Neurology, University of Muenster, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernward Winter, MSc</last_name>
    <phone>+49-251-83</phone>
    <phone_ext>45695</phone_ext>
    <email>bwinter@uni-muenster.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Muenster, Department of Neurology</name>
      <address>
        <city>Muenster</city>
        <state>North-Rhine Westphalia</state>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://neurologie.uni-muenster.de/cms/front_content.php</url>
    <description>Dept. of Neurology, University of Muenster</description>
  </link>
  <reference>
    <citation>Knecht S, Breitenstein C, Bushuven S, Wailke S, Kamping S, Fl√∂el A, Zwitserlood P, Ringelstein EB. Levodopa: faster and better word learning in normal humans. Ann Neurol. 2004 Jul;56(1):20-6.</citation>
    <PMID>15236398</PMID>
  </reference>
  <reference>
    <citation>Breitenstein C, Knecht S. [Language acquisition and statistical learning]. Nervenarzt. 2003 Feb;74(2):133-43. Review. German.</citation>
    <PMID>12596014</PMID>
  </reference>
  <reference>
    <citation>Floel A, Hummel F, Breitenstein C, Knecht S, Cohen LG. Dopaminergic effects on encoding of a motor memory in chronic stroke. Neurology. 2005 Aug 9;65(3):472-4.</citation>
    <PMID>16087920</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>October 24, 2007</last_update_submitted>
  <last_update_submitted_qc>October 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2007</last_update_posted>
  <keyword>Dementia</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>MCI</keyword>
  <keyword>levodopa</keyword>
  <keyword>learning</keyword>
  <keyword>enhancement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

